IL313999A - Deuterated organic compounds and uses thereof - Google Patents

Deuterated organic compounds and uses thereof

Info

Publication number
IL313999A
IL313999A IL313999A IL31399924A IL313999A IL 313999 A IL313999 A IL 313999A IL 313999 A IL313999 A IL 313999A IL 31399924 A IL31399924 A IL 31399924A IL 313999 A IL313999 A IL 313999A
Authority
IL
Israel
Prior art keywords
organic compounds
deuterated organic
deuterated
compounds
organic
Prior art date
Application number
IL313999A
Other languages
English (en)
Hebrew (he)
Original Assignee
Engrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engrail Therapeutics Inc filed Critical Engrail Therapeutics Inc
Publication of IL313999A publication Critical patent/IL313999A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL313999A 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof IL313999A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263296137P 2022-01-03 2022-01-03
US202263314466P 2022-02-27 2022-02-27
US202263345002P 2022-05-23 2022-05-23
US202263394565P 2022-08-02 2022-08-02
US202263384988P 2022-11-25 2022-11-25
PCT/US2023/010055 WO2023130119A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Publications (1)

Publication Number Publication Date
IL313999A true IL313999A (en) 2024-08-01

Family

ID=87000385

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313999A IL313999A (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Country Status (10)

Country Link
US (1) US12606523B2 (cg-RX-API-DMAC10.html)
EP (1) EP4460292A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025501411A (cg-RX-API-DMAC10.html)
KR (1) KR20240132477A (cg-RX-API-DMAC10.html)
AU (1) AU2023204433B2 (cg-RX-API-DMAC10.html)
CA (1) CA3242755A1 (cg-RX-API-DMAC10.html)
IL (1) IL313999A (cg-RX-API-DMAC10.html)
MX (1) MX2024008371A (cg-RX-API-DMAC10.html)
TW (1) TW202333671A (cg-RX-API-DMAC10.html)
WO (1) WO2023130119A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025010255A2 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof
WO2026011157A1 (en) 2024-07-05 2026-01-08 Engrail Therapeutics, Inc. Crystalline forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197243A (en) * 1975-04-02 1980-04-08 Yamanouchi Pharmaceutical Co., Ltd. N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives
US4210660A (en) 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
TW212139B (cg-RX-API-DMAC10.html) 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
KR100355130B1 (ko) 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
US5705498A (en) 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN104744333A (zh) 2013-12-26 2015-07-01 张云 一种奈莫必利的生产方法
US20190343827A1 (en) 2018-05-08 2019-11-14 Izumi Technology, Llc Deuterated analogs of tariquidar
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
US20210017160A1 (en) 2019-07-16 2021-01-21 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
JP2025501410A (ja) 2022-01-03 2025-01-17 エングレイル・セラピューティクス・インコーポレイテッド 重水素化有機化合物およびその使用
WO2025010255A2 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof

Also Published As

Publication number Publication date
US20250011280A1 (en) 2025-01-09
KR20240132477A (ko) 2024-09-03
AU2023204433A1 (en) 2024-07-18
WO2023130119A1 (en) 2023-07-06
MX2024008371A (es) 2024-12-06
AU2023204433B2 (en) 2026-07-30
EP4460292A4 (en) 2025-07-16
CA3242755A1 (en) 2023-07-06
JP2025501411A (ja) 2025-01-17
TW202333671A (zh) 2023-09-01
EP4460292A1 (en) 2024-11-13
US12606523B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
KR20250018170A (ko) 유기 화합물 및 이의 응용
IL314019A (en) Deuterated organic compounds and their uses
EP4163980A4 (en) OLED SCREENBOARD
IL325390A (en) Deuterated organic compounds and their uses
EP4130014A4 (en) Deuterated oxophenylarsine compound and use thereof
JP1787418S (ja) タンブラー
EP4089156A4 (en) Organic electroluminescence element
EP4392028A4 (en) DEUTERATED EMPATHOGENS
JP1788753S (ja) タンブラー
JP1752540S (ja) タンブラー
EP4143405C0 (en) PADLOCK
EP4460292A4 (en) DEUTERATED ORGANIC COMPOUNDS AND THEIR USES
EP4465785A4 (en) HOUSING
JP1782685S (ja) タンブラー
JP1775783S (ja) ハンドバッグ
KR20240099208A9 (ko) EGFRvIII-표적화 화합물 및 그의 용도
JP1736693S (ja) タンブラー
JP1735084S (ja) タンブラー
IT202200002996A1 (it) Scintillatore organico
JP1761936S (ja) ノート
JP1761938S (ja) ノート
JP1761937S (ja) ノート
JP1741985S (ja) ブリーフケース
JP1767384S (ja) スーツケース
JP1733073S (ja) ブリーフケース